KR20160145323A - Composition comprising fermented Allium hookeri for preventing and treating obesity - Google Patents
Composition comprising fermented Allium hookeri for preventing and treating obesity Download PDFInfo
- Publication number
- KR20160145323A KR20160145323A KR1020150081737A KR20150081737A KR20160145323A KR 20160145323 A KR20160145323 A KR 20160145323A KR 1020150081737 A KR1020150081737 A KR 1020150081737A KR 20150081737 A KR20150081737 A KR 20150081737A KR 20160145323 A KR20160145323 A KR 20160145323A
- Authority
- KR
- South Korea
- Prior art keywords
- fermented
- preventing
- obesity
- present
- treating obesity
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 36
- 235000020824 obesity Nutrition 0.000 title claims abstract description 36
- 241001513212 Allium hookeri Species 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title claims description 16
- 238000000855 fermentation Methods 0.000 claims abstract description 33
- 230000004151 fermentation Effects 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 235000013376 functional food Nutrition 0.000 claims description 7
- 240000006439 Aspergillus oryzae Species 0.000 claims description 6
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 24
- 150000004684 trihydrates Chemical class 0.000 abstract description 12
- 210000000577 adipose tissue Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 10
- 235000009200 high fat diet Nutrition 0.000 abstract description 8
- 230000037396 body weight Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 description 15
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000010171 animal model Methods 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010033307 Overweight Diseases 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000032683 aging Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000134253 Lanka Species 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000877401 Saccharomyces ellipsoideus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000019654 spicy taste Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Fermentation of the present invention, three (Allium hookeri ) showed a decrease in body weight, body fat weight and blood cholesterol level compared with non-fermented trihydrate when fed with a high fat diet in a rat. Thus, the fermented trihydrate could be used as a pharmaceutical composition for the prevention and treatment of obesity, . ≪ / RTI >
Description
The present invention into effect three (Allium hookeri ) as an active ingredient, or a health functional food.
Recent changes in diet and eating habits have been accompanied by changes in economic growth and lifestyle. Especially, busy modern people are overweight and obese because of high calorie diet such as fast food and low exercise amount. Weight overweight means that the body mass index (BMI, obesity index divided by the square of body weight) is 25 or more and less than 30, and obesity means the body mass index is 30 or more. Two-thirds of US adults are overweight or obese, and overweight increases blood pressure and cholesterol levels, increasing the incidence of various adult diseases, including heart disease. The effects of obesity on various diseases are so severe that it is known that 80% of diabetics worldwide and 21% of heart disease are caused by obesity. In addition, various cancers such as uterine cancer, kidney cancer, and breast cancer are directly or indirectly related to obesity. Obesity and overweight also have higher incidences of sleep apnea, osteoarthritis, and gallstone disease than normal people (Stein CJ, Colditz GA. The epidemic of J Clin Endocrinol Metab 2004; 89: 2522-2525; Kopelman PG, Obesity as a medical problem, Nature 2000 Apr 6; 404 (6778): 635-43).
Obesity is not caused by a single cause, but by a combination of genetic, environmental, social, and mental factors. Current methods of treating obesity include diet, exercise, and behavioral therapy, as well as methods of correcting lifestyle, drug therapy, and surgical treatment. Although active efforts should be made to correct lifestyle prior to medication or surgical treatment, it is not easy to correct lifestyle habits, and there is a limit to the weight that can be reduced by lifestyle correction alone. Therefore, in many cases, lifestyle correction and medication are necessary.
Although many anti-obesity agents are being developed every year for the treatment of obesity, there are not many obesity agents available at present, and most of them are limited to digestive or appetite-suppressing agents. In the case of digestive or appetite control agents, they are classified as psychotropic drugs because of habit, and digestion inhibitors show side effects such as diarrhea and constipation. By 2010, the US FDA approved long-term obesity treatment drugs include norepinephrine, sibutramine (Reductil), which suppresses the reabsorption of serotonin, and pancreatic and digestive machines (Orlistat; Xenical), which inhibits the lipase that is produced in the body (Yanovski SZ, Yanovski JA Obesity, N Engl J Med 2002; 346: 591-602). However, sibutramine has been withdrawn in the US and Korea in October 2010 due to the risk of cardiovascular events such as myocardial infarction and stroke, which are common with side effects such as elevated blood pressure, insomnia, dry mouth and dizziness. In addition, Orristat has been reported to have side effects such as diarrhea, fatty liver, loss of gold, etc. When the fat intake is lower than that of westerners like Koreans, the effect of the drug is not clear and its use is limited (Kim, Sangman. 1998; 7 (4): 287-92.). Therefore, there is not yet a drug for obesity which has a good effect of suppressing obesity and has been confirmed to be safe for long-term use. Therefore, there is a need for a preventive and therapeutic agent for obesity.
Allium hookeri are distributed in southern China, India, Bhutan, Sri Lanka, etc. in East Asia and grow in forests, wetlands and grasslands of 1400 m to 4200 m above sea level. It is also called "Root Leek". It is also called "玄 菜" because its taste and shape are similar to ginseng. It is also called "三 菜" because it has three flavors of bitter taste, sweet taste and spicy taste. The height of the plant is about 0.6 to 1 m, and it is known that the roots, leaves and flowers of the three-leafed plants can be used for food and medicinal use. However, there is no known effect on the prevention and treatment of obesity.
The present inventors have conducted studies to develop a preventive and therapeutic agent for obesity derived from natural products without toxicity and side effects. As a result, when fermented syrup was mixed with a high fat diet in rats, the weight, And confirming that the cholesterol level is reduced, the present inventors have completed the present invention by confirming that the fermented trifoliate can be used as an agent for preventing and treating obesity.
An object of the present invention into effect three (Allium hookeri ) as an active ingredient, and a health functional food.
In order to achieve the above object, the present invention into effect three (Allium hookeri ) as an active ingredient.
The present invention also provides a health functional food for prevention and improvement of obesity containing fermented trihydrate as an active ingredient.
Fermentation of the present invention, three (Allium hookeri ) showed a decrease in body weight, body fat weight and blood cholesterol level compared with non-fermented triplex when they were mixed with high fat diets in rats. Thus, the fermented triplets were found to be useful as a pharmaceutical composition for preventing and treating obesity, . ≪ / RTI >
FIG. 1 is a view showing a method for producing a fermented triangle; FIG.
FIG. 2 is a chart showing weight loss in fermented triplicate rats. FIG.
FIG. 3 is a graph showing weight loss of body fat in a fermented triad of rats.
FIG. 4 is a graph showing blood cholesterol reduction in fermented triplicate rats. FIG.
Hereinafter, the present invention will be described in detail.
The present invention into effect three (Allium hookeri ) as an active ingredient.
The fermented syrup is preferably but not limited to be produced by a process comprising the steps of:
1) preparing a yeast fermentation broth;
2) preparing a natural enzyme culture;
3) mixing the yeast fermentation broth of step 1) and the natural enzyme broth of step 2); And
4) adding the dried triplet to the mixed culture of step 3) to ferment.
The mixing of the step 3) is preferably performed by mixing the yeast fermentation broth and the natural enzyme culture broth at a weight ratio of 1: 1, but is not limited thereto.
It is preferable that the triplet of step 4) is leaf, roots or flower of a triangle, more preferably a root, but is not limited thereto.
The triplex of step 4) above can be used without limitation such as cultivated or marketed.
The mixed culture medium of step 4) and the dried triplex are preferably mixed at a weight ratio of 1: 1, but the present invention is not limited thereto.
The fermentation of step 4) is preferably performed at 40 to 70 ° C, more preferably 50 to 60 ° C, and is preferably performed 3 times, but is not limited thereto.
Preferably, the fermented triplex further comprises aging the fermented triangle after fermentation, but the present invention is not limited thereto.
The aging is preferably performed for 3 days through a convection heat circulation method at 40 to 50 캜 and a wet heating using convection heat at a humidity of 40 to 60%, but is not limited thereto.
The yeast fermentation broth may be any one or more strains selected from the group consisting of Aspergillus oryzae, Saccharomyces ellipsoideus and Saccharomyces cerevisiae. And it is more preferable that it is manufactured from Aspergillus oryzae, but not limited thereto.
In a specific example of the present invention, the present inventors prepared a fermented triangle using a three-rooted root (see Fig. 1). The fermented triangle roots were fed to a high fat diet of rats and fed for 8 weeks. (Fig. 2). As a result of examining the change in the body fat weight, it was confirmed that the roots of the fermented tuberous roots were less than those of the non-fermented tubers or the untreated roots As a result, it was confirmed that the weight of the adipose tissue was reduced by 19% or more compared to the untreated group in which the rats were not fed with the non-fermented trihydrate or triple root (see FIG. 3). As a result of checking the change of the blood cholesterol level, Root-fed rats showed a 22% decrease in their blood cholesterol levels compared to the non-fermented group or the untreated control group Was (see Fig. 4).
Therefore, when the fermented trihydrate of the present invention is mixed with a high fat diet in rats, it is confirmed that weight, body fat weight and blood cholesterol level are reduced, and thus the fermented trihydrate is usefully used as a pharmaceutical composition for the prevention and treatment of obesity .
The compositions of the present invention may be of various oral or parenteral formulations. When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used.
Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions or syrups. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances or preservatives are included .
Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations or suppositories. Examples of non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. As a base for suppositories, witepsol, macrogol, tween 61, cacao paper, laurin, glycerol, gelatin and the like can be used.
The composition of the present invention may be administered orally or parenterally, and it is preferable to select the intraperitoneal, rectal, rectal, intravenous, intramuscular, subcutaneous, intrauterine or intracerebral injection methods during parenteral administration.
The composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, the effective dose level is determined according to the kind of the patient's disease, the severity, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the period of treatment, Can be determined according to well-known factors. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, This can be readily determined by one skilled in the art.
The dosage of the composition of the present invention varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of disease, The dose is 0.01 to 1000 mg / kg, preferably 30 to 500 mg / kg, more preferably 50 to 300 mg / kg, and can be administered 1 to 6 times a day. However, the dosage may be varied depending on the route of administration, the severity of obesity, sex, weight, age, etc. Therefore, the dosage is not limited to the scope of the present invention by any means.
The composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.
The present invention also provides a health functional food for prevention and improvement of obesity containing fermented trihydrate as an active ingredient.
The fermented syrup is preferably but not limited to be produced by a process comprising the steps of:
1) preparing a yeast fermentation broth;
2) preparing a natural enzyme culture;
3) mixing the yeast fermentation broth of step 1) and the natural enzyme broth of step 2); And
4) adding the dried triplet to the mixed culture of step 3) to ferment.
The mixing of the step 3) is preferably performed by mixing the yeast fermentation broth and the natural enzyme culture broth at a weight ratio of 1: 1, but is not limited thereto.
It is preferable that the triplet of step 4) is leaf, roots or flower of a triangle, more preferably a root, but is not limited thereto.
The triplex of step 4) above can be used without limitation such as cultivated or marketed.
The mixed culture medium of step 4) and the dried triplex are preferably mixed at a weight ratio of 1: 1, but the present invention is not limited thereto.
The fermentation of step 4) is preferably performed at 40 to 70 ° C, more preferably 50 to 60 ° C, and is preferably performed 3 times, but is not limited thereto.
Preferably, the fermented triplex further comprises aging the fermented triangle after fermentation, but the present invention is not limited thereto.
The aging is preferably performed for 3 days through a convection heat circulation method at 40 to 50 캜 and a wet heating using convection heat at a humidity of 40 to 60%, but is not limited thereto.
It is preferable that the yeast fermentation broth is produced from any one or more strains selected from the group consisting of Aspergillus oryzae, Saccharomyces ellipsoides, and Saccharomyces cerevisiae, and the aspergillus oryzae strains But it is not limited thereto.
When the fermented trihydrate of the present invention is mixed with a high fat diet in rats, it is confirmed that weight, body fat weight and blood cholesterol level are reduced, so that the fermented triangle can be usefully used as a health functional food for preventing and improving obesity .
The health functional food may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and rings, but is not limited thereto and may be manufactured and processed in any form according to the law.
The fermented trihydrate of the present invention can be added directly to the food or used together with other food or food ingredients, and can be suitably used according to conventional methods. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (for prevention or improvement). Generally, the amount of the fermented trihydrate in the health food may be 0.1 to 90 parts by weight of the total food. However, in the case of long-term ingestion intended for health and hygiene purposes or health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount in the above range.
The health functional beverage composition of the present invention is not particularly limited to the other ingredients except that the fermented trihydrate is contained as an essential ingredient at the indicated ratio and may contain various flavors or natural carbohydrates as an additional ingredient have. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above .
In addition to the above, the fermented syrup of the present invention can be used as a flavoring agent such as a variety of nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate, etc.), pectic acid and its salts, Salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the fermented triangle of the present invention can contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of from 0.1 to about 10 parts by weight per 100 parts by weight of the fermented slab of the present invention.
Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples.
However, the following examples and experimental examples are illustrative of the present invention, and the content of the present invention is not limited by the following examples and experimental examples.
< Example 1> Fermented milk Allium hookeri )
Fermented triplexes were prepared as shown in Fig. First, 50 ml of purified water was added to 2 g of Aspergillus Oryzae yeast culture concentrated powder (1.0 × 10 9 cfu / g), and 50 ml of purified water was added to 1 g of yeast fermentation broth homogenously mixed with fruit enzyme concentrate To prepare homogeneously mixed natural enzyme cultures. The prepared yeast fermentation broth and natural enzyme culture broth were mixed and 900 ml of purified water was added thereto to prepare 1,000 ml of a yeast-enzyme complex fermentation broth.
After washing, the leaves and roots were separated, and then dried at a temperature of 70 ° C for 12 hours. Then, 500 g of the dry triangular root was taken and placed in a tray for fermentation , And the mixture was immersed in 500 ml of the yeast-enzyme complex fermentation broth and allowed to stand at room temperature for 24 hours. The fermentation broth was placed in a fermenter, and the mixture was firstly fermented for 5 days while maintaining the temperature at 50 to 60 ° C. Then, 250 ml of the yeast-enzyme complex fermentation broth was sprayed, followed by secondary fermentation under the same conditions. After spraying, the third fermentation was carried out. After the third fermentation, it was aged for 3 days by convection heat circulation method and maintaining the humidity of 40 ~ 60% at a temperature of 40 ~ 50 ℃ and convection heat for 3 days. Then, it was ventilated at 30 ~ (Fig. 1).
< Example 2> Preparation of experimental animals
C57BLKS / J-db / db (db / db) mice (type 2 diabetes and obesity) used as experimental animals were purchased from the Central Laboratory Animals Co., (About 1% in high fat diets (45%)) and non fermented diets (about 1% in high fat diets (45%)) Eight weeks were given freely. The temperature of the laboratory animal room was 24 ± 1 and the humidity was 55 ± 5%. Breeding control of laboratory animals complied with the deliberation of the animal ethics committee of the National Academy of Agricultural Science.
< Experimental Example 1> On the trunk Check for changes in body weight
The change in body weight of the fermented triad of the present invention was confirmed.
Specifically, using the experimental animals of Example 2, in which the fermented triplets of Example 1 were taken, no triplet (no treatment), no fermentation triplet (non-fermented triplet), and fermented triplet (45%) diets were fed for 8 weeks, and body weights were measured using laboratory animal scales.
As a result, as shown in Fig. 2, it was confirmed that the weight of the rats fed with the fermented triplet roots was reduced by 9.2% or more (Fig. 2) compared with the non-fermented triplet or the untreated roots.
< Experimental Example 2> On the trunk Body fat by of Confirm change
The weight change of the body fat of the fermented triangle of the present invention was confirmed.
Specifically, using the experimental animals of Example 2, in which the fermented triplets of Example 1 were taken, no triplet (no treatment), no fermentation triplet (non-fermented triplet), and fermented triplet (45%) diets were fed for 8 weeks. After the animals were euthanized, the weight of the adipose tissue collected from the abdomen was measured using an animal scales.
As a result, as shown in Fig. 3, it was confirmed that the weight of adipose tissue was reduced by 19% or more as compared with the untreated group in which the fermented tuberculosis roots were not fed the nonfermented tuberculosis group or the tuberous root (Fig. 3) .
< Experimental Example 3> On the trunk Of cholesterol
The change in blood cholesterol level in the rats caused by the fermented triplex of the present invention was confirmed.
Specifically, using the experimental animals of Example 2, in which the fermented triplets of Example 1 were taken, no triplet (no treatment), no fermentation triplet (non-fermented triplet), and fermented triplet After high-fat (45%) diets were fed for 8 weeks, the blood was obtained from the experimental animals and treated with a total cholesterol-measuring reagent (Asan Pharmaceutical Co., Ltd.) and the absorbance was measured at 500 nm.
As a result, as shown in Fig. 4, the blood cholesterol level was reduced by 22% or more (Fig. 4), compared with the non-fermented group or the untreated group not consuming the three-rooted root.
Claims (8)
1) preparing a yeast fermentation broth;
2) preparing a natural enzyme culture;
3) mixing the yeast fermentation broth of step 1) and the natural enzyme broth of step 2); And
4) adding the dried triplets to the mixed culture solution of step 3), and fermenting the mixture.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150081737A KR101782969B1 (en) | 2015-06-10 | 2015-06-10 | Composition comprising fermented Allium hookeri for preventing and treating obesity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150081737A KR101782969B1 (en) | 2015-06-10 | 2015-06-10 | Composition comprising fermented Allium hookeri for preventing and treating obesity |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20160145323A true KR20160145323A (en) | 2016-12-20 |
KR101782969B1 KR101782969B1 (en) | 2017-09-28 |
Family
ID=57734164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150081737A KR101782969B1 (en) | 2015-06-10 | 2015-06-10 | Composition comprising fermented Allium hookeri for preventing and treating obesity |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101782969B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101879552B1 (en) * | 2017-12-27 | 2018-07-17 | 정주호 | Mul-Kimchi using allium hookeri and method thereof |
KR20210133491A (en) * | 2020-04-29 | 2021-11-08 | 대한민국(농촌진흥청장) | Health functional food composition for improving cognitive ability comprising an extract of Allium hookeri |
KR102337130B1 (en) * | 2021-07-20 | 2021-12-10 | 유동민 | Composition comprising fermented Oriental medicine herbs for preventing, improving or treating obesity, and method for preparing the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101441609B1 (en) | 2013-04-05 | 2014-09-24 | 김호현 | Composition comprising extract of Allium hookeri for preventing or treating of metabolic diseases |
KR101552970B1 (en) | 2014-03-04 | 2015-09-15 | 순천대학교 산학협력단 | Composition for improving liver function or protecting liver damage Comprising Allium Hookeri Extract |
KR101663379B1 (en) | 2014-11-07 | 2016-10-07 | 전북대학교산학협력단 | MANUFACTURE OF FERMENTED Allium hookeri FROM YEASTS AND NATURAL ENZYME AND PREPARATION OF COMBINED BEVERAGE FOR QUENCHING THIRST |
-
2015
- 2015-06-10 KR KR1020150081737A patent/KR101782969B1/en active IP Right Grant
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101879552B1 (en) * | 2017-12-27 | 2018-07-17 | 정주호 | Mul-Kimchi using allium hookeri and method thereof |
KR20210133491A (en) * | 2020-04-29 | 2021-11-08 | 대한민국(농촌진흥청장) | Health functional food composition for improving cognitive ability comprising an extract of Allium hookeri |
KR102337130B1 (en) * | 2021-07-20 | 2021-12-10 | 유동민 | Composition comprising fermented Oriental medicine herbs for preventing, improving or treating obesity, and method for preparing the same |
Also Published As
Publication number | Publication date |
---|---|
KR101782969B1 (en) | 2017-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102130332B1 (en) | Health fuctional food composition for preventing or improving liver diseases comprising Gastrodia elata and larva | |
KR101559130B1 (en) | Composition comprising herbal extract for preventing or treating obesity | |
KR101782969B1 (en) | Composition comprising fermented Allium hookeri for preventing and treating obesity | |
US20180296615A1 (en) | Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient | |
KR20220132349A (en) | Composition for preventing, ameliorating or treating metabolic disease comprising leaf extract of new pepper cultivar as effective component | |
KR101935848B1 (en) | Food composition for improving hyperglycemia using Brassica rapa | |
KR101446528B1 (en) | Vinegar Composition Fermented with Black Garlic and Preparation Method Thereof | |
KR101735061B1 (en) | Composition containing Artemisia annua extract, artemisinin or dihydroartemisinin for preventing or treating obesity | |
KR102151011B1 (en) | Composition for preventing, improving or treating liver disease comprising fermented liquor of aged sprout ginseng extract as effective component | |
KR102337130B1 (en) | Composition comprising fermented Oriental medicine herbs for preventing, improving or treating obesity, and method for preparing the same | |
KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
KR20190053108A (en) | A composition comprising the complex extract for antiobesity of men | |
US20100093852A1 (en) | Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizon for treating or preventing diabetes mellitus and the use thereof | |
KR101591460B1 (en) | Composition comprising mixture extract of Ephedra sinica, Rheum palmatum L and Arnebia euchroma for preventing or treating obesity | |
KR101336068B1 (en) | Anti-diabetes composition comprising oriental herbal extracts and fractions | |
KR101330687B1 (en) | Composition for treating and preventing obesity containing oriental herbal extracts | |
KR101811210B1 (en) | Composition for treatment, improvement or prevention of Diabetes comprising extract of fruit of Sorbus commixta as an effective component | |
KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
US20230055551A1 (en) | Pharmaceutical composition for preventing or treating nonalcoholic steatohepatitis containing aster koraiensis nakai extract | |
KR20110118748A (en) | Compositions for prevention and improvement of cancer containing the extracts of ligularia fischeri var. spiciformis nakai as an active ingredient | |
KR20170055366A (en) | A composition for preventing or treating obesity comprising taraxacum coreanum root extract | |
KR101406126B1 (en) | Composition containing Hedyotis diffusa extract for treating or preventing obesity | |
KR101904819B1 (en) | Composition comprising Fermented Momordica charantia L. and Allium sativum L. using Amyloliquefaciens Bacillus Jis-1 for lowering blood glucose or preventing and treating diabetes mellitus | |
KR101498464B1 (en) | Composition comprising mixture extract of Panax ginseng and Veratrum nigrum L. for preventing or treating obesity | |
KR101419826B1 (en) | Anti-obesity composition comprising oriental herbal extracts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |